Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab open-label extension in severe eosinophilic asthma
2023-505203-23-01Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 3, open-label, single-arm trial of depemokimab in eosinophilic asthma (EA), sponsored by GSK. Primary endpoints: Incidence of adverse events and serious adverse events and Incidence of immunogenicity. Started Jul 2021; status: completed.
02
Drugs
depemokimab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2023-505203-23-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505203-23-01.